

Elisabetta El Loggi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9568190/publications.pdf>

Version: 2024-02-01

33
papers

1,584
citations

516561

16
h-index

395590

33
g-index

34
all docs

34
docs citations

34
times ranked

2521
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiviral Intrahepatic T-Cell Responses Can Be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B. <i>Gastroenterology</i> , 2010, 138, 682-693.e4.	0.6	416
2	Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. <i>Journal of Hepatology</i> , 2013, 58, 225-233.	1.8	202
3	Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire. <i>Journal of Virology</i> , 2008, 82, 10986-10997.	1.5	114
4	Combined Blockade of Programmed Death-1 and Activation of CD137 Increase Responses of Human Liver T Cells Against HBV, But Not HCV. <i>Gastroenterology</i> , 2012, 143, 1576-1585.e4.	0.6	106
5	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017, 37, 514-528.	1.9	84
6	HIV Patients Developing Primary CNS Lymphoma Lack EBV-Specific CD4+ T Cell Function Irrespective of Absolute CD4+ T Cell Counts. <i>PLoS Medicine</i> , 2007, 4, e96.	3.9	81
7	Mobilization of Bone Marrow-Derived Hematopoietic and Endothelial Stem Cells After Orthotopic Liver Transplantation and Liver Resection. <i>Stem Cells</i> , 2006, 24, 2817-2825.	1.4	79
8	Peginterferon- α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. <i>Journal of Hepatology</i> , 2012, 56, 1239-1246.	1.8	75
9	Liver transplantation from hepatitis B surface antigen positive donors: A safe way to expand the donor pool. <i>Journal of Hepatology</i> , 2012, 56, 579-585.	1.8	64
10	Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBeAg positive graft. <i>Journal of Hepatology</i> , 2009, 50, 625-630.	1.8	46
11	Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. <i>Annals of Hepatology</i> , 2018, 17, 64-75.	0.6	46
12	Virus-Specific Immune Response in HBeAg-Negative Chronic Hepatitis B: Relationship with Clinical Profile and HBeAg Serum Levels. <i>PLoS ONE</i> , 2013, 8, e65327.	1.1	36
13	Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". <i>Journal of Translational Medicine</i> , 2005, 3, 20.	1.8	34
14	Liver grafts from hepatitis B surface antigen-positive donors: A review of the literature. <i>World Journal of Gastroenterology</i> , 2016, 22, 8010.	1.4	21
15	Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. <i>Journal of Clinical Virology</i> , 2013, 56, 291-295.	1.6	18
16	Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods. <i>PLoS ONE</i> , 2017, 12, e0187755.	1.1	18
17	Chronic hepatitis B: Are we close to a cure?. <i>Digestive and Liver Disease</i> , 2015, 47, 836-841.	0.4	17
18	The function of specialized pro-resolving endogenous lipid mediators, vitamins, and other micronutrients in the control of the inflammatory processes: Possible role in patients with SARS-CoV-2 related infection. <i>Prostaglandins and Other Lipid Mediators</i> , 2022, 159, 106619.	1.0	16

#	ARTICLE	IF	CITATIONS
19	Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBsAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 568-575.	1.0	15
20	In vitro effect of indomethacin and interferon- γ on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C. <i>Cytokine</i> , 2004, 26, 95-101.	1.4	12
21	SARS-CoV-2: lessons from both the history of medicine and from the biological behavior of other well-known viruses. <i>Future Microbiology</i> , 2021, 16, 1105-1133.	1.0	11
22	Vitamins in the treatment of chronic viral hepatitis. <i>British Journal of Nutrition</i> , 2011, 105, 982-989.	1.2	10
23	Effect of Liver Transplantation on Tuftsin Activity and Phagocytic Activity of Neutrophil Granulocytes in Patients with Liver Cirrhosis. <i>International Archives of Allergy and Immunology</i> , 2005, 137, 258-262.	0.9	7
24	Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies. <i>Hepatology International</i> , 2015, 9, 586-593.	1.9	7
25	Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection. <i>Liver Transplantation</i> , 2008, 14, 478-485.	1.3	6
26	Vitamin E for the treatment of E antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. <i>Liver International</i> , 2017, 37, 54-61.	1.9	5
27	Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. <i>World Journal of Gastroenterology</i> , 2009, 15, 5946.	1.4	3
28	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. <i>Italian Journal of Medicine</i> , 2011, 5, 82-89.	0.2	1
29	Gold standard assays for the monitoring of patients with chronic hepatitis C. <i>Future Virology</i> , 2018, 13, 529-537.	0.9	1
30	Polymorphism rtQ215H in primary resistance to adefovir dipivoxil in hepatitis B virus infection: a case report. <i>BMJ Case Reports</i> , 2009, 2009, bcr0620080287-bcr0620080287.	0.2	1
31	Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. <i>Annals of Hepatology</i> , 2014, 13, 196-203.	0.6	1
32	Virological Treatment Monitoring for Chronic Hepatitis B. <i>Viruses</i> , 2022, 14, 1376.	1.5	1
33	The pharmacology and activity of non-steroidal anti-inflammatory drugs (NSAIDs): a review of their use as an adjuvant treatment in patients with HBV and HCV chronic hepatitis. <i>Italian Journal of Medicine</i> , 0, , 82-89.	0.2	0